Seeking To Redefine What Is Possible®
Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company is developing innovative therapies for neuropsychiatric disorders.
Promentis’ drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders.
The Company’s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.
A growing roster of recognized leaders in the biopharmaceutical industry and clinical experts in CNS disorders